Physician profile
Eric Horst
NPI 1922088483
$28,602.44
in general payments reported to CMS, 2019-2025
59 companies · $2,958 in 2025
The $2,958 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,197 · 2021: $936 · 2022: $2,423 · 2023: $3,234 · 2024: $3,007 · 2025: $2,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,178 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,177.99 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $13,482.82 | 2019-2025 | |
| Lilly USA, LLC | $2,091.12 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Insulet Corporation | $1,207.95 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $1,025.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $914.92 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $695.86 | 2022-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $654.75 | 2019-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $597.61 | 2019-2025 | Tirosint, Tirosint, Licart |
| Astrazeneca Pharmaceuticals Lp | $593.21 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $551.67 | 2019-2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $532.47 | 2019-2025 | Unithroid |
| Amgen INC. | $490.60 | 2019-2025 | Tepezza, Repatha, Evenity |
| Medtronic, INC. | $472.66 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbvie INC. | $414.65 | 2019-2024 | |
| Mannkind Corporation | $407.37 | 2019-2025 | Afrezza |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $289.97 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Tandem Diabetes Care, INC. | $268.71 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $266.27 | 2019-2020 | |
| Lifescan, INC. | $247.14 | 2019-2023 | |
| Recordati_rare_diseases_inc. | $226.66 | 2022-2025 | Isturisa, Signifor Lar |
| Radius Health, INC. | $225.61 | 2019-2025 | |
| Shire North American Group INC | $215.94 | 2019 | |
| Horizon Therapeutics Plc | $208.18 | 2020-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $198.60 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $172.29 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $160.94 | 2023-2025 | Yorvipath |
| Corcept Therapeutics | $160.11 | 2020-2025 | Korlym |
| Neurocrine Biosciences, INC. | $160.00 | 2024-2025 | Crenessity |
| Ascensia Diabetes Care US INC. | $158.58 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.79 | 2020-2022 | |
| Sequel Med Tech, LLC | $139.25 | 2025 | Twiist |
| Cequr Corporation | $130.99 | 2023-2025 | Cequr Simplicity |
| Becton, Dickinson and Company | $121.71 | 2019-2022 | |
| Valeritas, INC. | $118.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $75.00 | 2024 | |
| Pfizer INC. | $73.96 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $71.25 | 2019-2020 | |
| Madrigal Pharmaceuticals | $68.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Ultragenyx Pharmaceutical INC. | $61.28 | 2020-2022 | |
| Companion Medical, INC. | $59.27 | 2019 | |
| Kyowa Kirin, INC. | $54.33 | 2024-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $44.85 | 2025 | Strensiq |
| Zealand Pharma US, INC. | $42.44 | 2021-2022 | |
| Tolmar, INC. | $32.85 | 2025 | Jatenzo |
| Janssen Pharmaceuticals, INC | $27.72 | 2020 | |
| Chiesi USA, INC. | $25.12 | 2025 | Mycapssa |
| Intuity Medical INC | $22.53 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amryt Pharma Holdings Ltd | $20.05 | 2022 | |
| Almatica Pharma LLC | $19.69 | 2025 | Teriparatide |
| Esperion Therapeutics, INC. | $18.77 | 2020 | |
| Astellas Pharma US INC | $18.34 | 2024 | Veozah |
| Eusa Pharma (US) LLC | $18.06 | 2022 | |
| Acella Pharmaceuticals, LLC | $17.46 | 2025 | NP Thyroid 60 |
| Azurity Pharmaceuticals, INC. | $15.16 | 2023 | Adthyza |
| Rgh Enterprises LLC | $15.15 | 2025 | |
| Acerus Pharmaceuticals Corporation | $14.66 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $14.52 | 2024 | Baqsimi |
| Roche Diabetes Care, INC. | $14.00 | 2019 | |
| Embecta Corp. | $12.74 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Horst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.